Obsidian Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Obsidian Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Obsidian Therapeutics, Inc. Common Stock (OBX) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-22.01 Million could theoretically repay 0% of its total liabilities ($346.33 Million) in one year. See Obsidian Therapeutics, Inc. Common Stock financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Obsidian Therapeutics, Inc. Common Stock (2024–2025)
Cash flow-to-debt ratio of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. Historical debt coverage capacity for Obsidian Therapeutics, Inc. Common Stock across 2 annual periods. Also explore Obsidian Therapeutics, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Obsidian Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2024–2025)
Obsidian Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for Obsidian Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see Obsidian Therapeutics, Inc. Common Stock (OBX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.25x | $-90.39 Million | $354.62 Million | ▼ -21.7% |
| 2024 | -0.21x | $-75.00 Million | $358.14 Million | — |